Targeted Therapies In Asthma: Update Bulletin [April 2016]

Targeted Therapies In Asthma: Update Bulletin [April 2016]

Code: FW-21072016-24 | Published: Apr-2016 | Pages: 0 | FirstWord
Price :
$995.00
USD

* Required Fields

$995.00

Details

This edition presents key opinion leader (KOL) views on recent developments in the asthma market, including the clinical role of Nucala (mepolizumab; GSK) the prospects for Teva’s recently approved Cinqair (reslizumab) and the future for lebrikizumab (Roche) following the disappointing LAVOLTA trial results.

Is Nucala an alternative to Xolair?
In patients eligible for Xolair and Nucala, which antibody do KOLs pick first and why?
Does Cinqair have any role? Are there any circumstances where it is preferred over Nucala?
What is the future for anti-IL13 antibodies?
Why might Roche conduct further studies with lebrikizumab?

Table of Contents

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord